Remission of Type 2 Diabetes Feasible With Soup and Shake Diet Intervention
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 9, 2024 -- A behavioral intervention designed to support weight loss can yield remission of type 2 diabetes, according to a study published online Aug. 5 in The Lancet Diabetes & Endocrinology.
Jonathan Valabhji, M.D., from NHS England in the United Kingdom, and colleagues assessed remission of type 2 diabetes among participants in the NHS Type 2 Diabetes Path to Remission program, a 12-month behavioral intervention to support weight loss, which included a three-month period of total diet replacement (composed of nutritionally formulated products such as soups, shakes, and bars and a total daily calorie intake of 800 to 900 kcal). A total of 1,740 participants started total diet replacement before January 2022 and had 12 months to complete the program by the time of data extraction in December 2022; 55 percent completed the program and had weight recorded at 12 months.
The researchers found that the mean weight loss for the 1,710 participants who started the program before January 2022 and had no missing data was 8.3 percent or 9.4 kg, and the mean weight loss was 9.3 percent or 10.3 kg for the 945 participants who completed the program and had no missing data. Overall, 27 percent of a subgroup of 710 participants who started the program before January 2022 and had two hemoglobin A1c (HbA1c) measurements recorded had remission, with mean weight loss of 13.4 percent or 14.8 kg. Among 450 participants who completed the program and had two HbA1c measurements recorded, 32 percent had remission, with mean weight loss of 14.4 percent or 15.9 kg.
"Remission is possible outside of research settings through at-scale delivery, although the rate of remission is less than those reported in randomized controlled trial settings," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Study Compares Benefits, Harms of Treatments for Chronic Hives
WEDNESDAY, July 23, 2025 -- Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
USPSTF Guidelines of Little Value for Estimating Preeclampsia Risk in Those at Moderate Risk
WEDNESDAY, July 23, 2025 -- Moderate U.S. Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.